Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT06349889 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).

NCT ID: NCT06331845 Not yet recruiting - Clinical trials for Metastatic Nasopharyngeal Carcinoma

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).

NCT ID: NCT06328868 Not yet recruiting - Dysphagia Clinical Trials

Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma

Start date: March 2024
Phase: N/A
Study type: Interventional

Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared. Palliation to delayed dysphagia after radiotherapy for nasopharyngeal carcinoma (NPC) continues to be a challenge. Although nasogastric tube feeding (NGT) has been adopted widely, the weaknesses have yet to be improved by another enteral nutrition support mode. This study aims to observe the clinical efficacy of intermittent oro-esophageal tube feeding (IOE) in the treatment of delayed dysphagia after radiotherapy for (NPC). This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received IOE while the control group received NGT for enteral nutrition support.

NCT ID: NCT06323239 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

NCT ID: NCT06301672 Not yet recruiting - Dysphagia Clinical Trials

Effect of Oral Enteral Nutrition in Nasopharyngeal Carcinoma Survivors With Swallowing Disorders

Start date: March 2024
Phase: N/A
Study type: Interventional

This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy. Patients enrolled are randomly divided equally into the observation group and the control group. All patients receive conventional care, and the observation group received Intermittent Oro-esophageal Tube Feeding while the control group received Nasogastric Tube Feeding for enteral nutrition support. Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life after treatment as well as adverse events are compared.

NCT ID: NCT06228079 Not yet recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial

NCT ID: NCT06197776 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Start date: April 1, 2024
Phase:
Study type: Observational

The observational clinical study will recruit 50 recurrent and/or metastatic nasopharyngeal carcinoma (r/mNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined with immunotherapy.

NCT ID: NCT06174012 Not yet recruiting - Sodium Fluoride Clinical Trials

The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in NPC Patients

Start date: December 15, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of sodium fluoride to preventing radiation caries for patients with nasopharyngeal carcinoma receiving radiotherapy.

NCT ID: NCT06136962 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Start date: December 1, 2023
Phase:
Study type: Observational

Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of research in head and neck radiation oncology have largely focused on improvements in survival, which have mostly come at the cost of long term toxicity for surviving patients.This is an observational study that is being done to evaluate the long-term efficacy, learn about the toxicity and quality of life that survivors of nasopharyngeal carcinoma may have following treated with reduced volume intensity modulated radiation therapy.

NCT ID: NCT06129201 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging

Start date: November 15, 2023
Phase:
Study type: Observational

Nasopharyngeal cancer is common in China, Southeast Asia, and North Africa, and is usually associated with Epstein-Barr virus (EBV) infection. Using EBV specific antibodies or EBV DNA screening can increase the proportion of patients diagnosed with early nasopharyngeal carcinoma from approximately 20% to over 70%. However, the application of nasopharyngeal carcinoma screening in clinical practice is hindered by low positive predictive values, even in areas where the EB virus is prevalent in China, the positive predictive value is only 4.8%. Therefore, there is an urgent need to identify new biomarkers or strategies with high sensitivity and positive predictive value for nasopharyngeal carcinoma screening. A study published in the Lancet sub journal 《eClinicalMedicine》 in 2023 showed that a tongue image model based on machine learning can serve as a stable diagnostic method for gastric cancer (AUC=0.89), and has been clinically validated in multiple centers. This study inspires researchers to introduce artificial intelligence machine learning technology into the diagnosis and treatment of nasopharyngeal cancer. In summary, this plan explores the establishment of tongue image machine learning models in nasopharyngeal carcinoma patients to help improve the positive predictive value of nasopharyngeal carcinoma screening.